Subscribe
shutterstock_1013219203_kateryna_kon
Kateryna Kon / Shutterstock.com
31 October 2019Big PharmaSaman Javed

Global Drug Facility adds new TB drug to its catalogue

The Global Drug Facility, which provides tuberculosis (TB) treatments to those in need in 150 countries, has listed a new drug to its product catalogue.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
TAG supports opposition of Sanofi TB drug patents in India
9 December 2019   Treatment Action Group, a US-based organisation focused on research of diseases such as HIV/AIDS and tuberculosis, has applauded an opposition that aims to block Sanofi from patenting a new TB drug in India.
Big Pharma
US considers shortening marketing exclusivity to push forward USMCA
3 December 2019   The Trump administration is considering shortening the period that big pharma companies’ biologic drugs are protected by marketing exclusivity from biosimilar competition.
Big Pharma
J&J invests $500m into global HIV and TB treatment
10 October 2019   Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
TAG supports opposition of Sanofi TB drug patents in India
9 December 2019   Treatment Action Group, a US-based organisation focused on research of diseases such as HIV/AIDS and tuberculosis, has applauded an opposition that aims to block Sanofi from patenting a new TB drug in India.
Big Pharma
US considers shortening marketing exclusivity to push forward USMCA
3 December 2019   The Trump administration is considering shortening the period that big pharma companies’ biologic drugs are protected by marketing exclusivity from biosimilar competition.
Big Pharma
J&J invests $500m into global HIV and TB treatment
10 October 2019   Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.

More on this story

Big Pharma
TAG supports opposition of Sanofi TB drug patents in India
9 December 2019   Treatment Action Group, a US-based organisation focused on research of diseases such as HIV/AIDS and tuberculosis, has applauded an opposition that aims to block Sanofi from patenting a new TB drug in India.
Big Pharma
US considers shortening marketing exclusivity to push forward USMCA
3 December 2019   The Trump administration is considering shortening the period that big pharma companies’ biologic drugs are protected by marketing exclusivity from biosimilar competition.
Big Pharma
J&J invests $500m into global HIV and TB treatment
10 October 2019   Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB